Piper Jaffray analyst Matt O'Brien believes the setup is favorable for shares of Globus Medical later this year and into 2017. A bump in sales rep postings on the company's website shows a confident outlook for the business next year, O'Brien tells investors in a research note. Further, Globus gets little credit for its robotics program, which is currently worth $2 per share, the analyst tells investors in a research note. He believes "patient investors" should start positions in the name at these levels. O'Brien has an Overweight rating on Globus with a $24 price target.